Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure

Advances in Therapy

Volumn 24, Issue 2, 2007, Pages 346-352

  Kanbay, Mehmet ^a,b   Akcay, Ali ^a   Delibasi, Tuncay ^b   Uz, Burak ^a   Kaya, Arif ^a   Koca, Cemile ^a   Turgut, Faruk ^a   Bavbek, Nuket ^a   Uz, Ebru ^a   Duranay, Murat ^b   Yigitoglu, Ramazan ^a  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^b Numune Research and Training Hospital ^*  (Turkey)

Author keywords

Blood pressure; Darbepoetin alfa; Endothelin; Epoetin alfa

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIALYSIS FLUID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; HEMOPHAN; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CHRONIC PYELONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROSCLEROSIS; KIDNEY POLYCYSTIC DISEASE; LOADING DRUG DOSE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

EID: 34250831487     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849903     Document Type: Article

References (25)

1. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med. 2004;164:262-276.
2. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989;321:158-163.
3. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant. 1989;4:979-987.
4. Roger SD, MacDougall IC, Thuraisingham RC, Raine AE. Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med. 1991;325:1175-1176.
5. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol. 1991;2:927-936.
6. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
7. Warrens AN, Cassidy MJ, Takahashi K, Ghatei MA, Bloom SR. Endothelin in renal failure. Nephrol Dial Transplant. 1990;5:418-422.
8. Saito Y, Kazuwa N, Shirakami G, et al. Endothelin in patients with chronic renal failure. J Cardiovasc Pharmacol. 1991;17(suppl 7):S437-S439.
9. Deray G, Carayon A, Maistre G, et al. Endothelin in chronic renal failure. Nephrol Dial Transplant. 1992;7:300-305.
10. Mortensen LH, Pawloski CM, Kanagy NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rats. Hypertension. 1990;15:729-733.
11. MacDougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16(suppl 3):14-21.
12. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538-548.
13. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 1991;39:259-265.
14. Tojo A, Doumoto M, Oka K, Numabe A, Kimura K, Yagi S. Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats. Am J Physiol. 1996;270:R744-R748.
15. Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol. 1991;261:E642-E646.
16. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996;50:1255-1261.
17. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91:3974-3978.
18. Miyashita K, Tojo A, Kimura K, et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res. 2004;27:79-84.
19. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol. 1992;20(suppl 12):S25-S28.
20. Liefeldt L, Schmidt-Ott KM, Orzechowski HD, Distler A, Paul M. Transcriptional regulation of endothelin-1 by erythropoietin in endothelial cells. J Cardiovasc Pharmacol. 1998;31(suppl 1):S464-S466.
21. Lopez Ongil SL, Saura M, Lamas S, Rodriguez Puyol M, Rodriguez Puyol D. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells. Exp Nephrol. 1996;4:37-42.
22. Shimada N, Saka S, Sekizuka K, et al. Increased endothelin:nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients. Ren Fail. 2003;25:569-578.
23. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol. 1995;269:F838-F845.
24. Moreau C, Lariviere R, Kingma I, Grose JH, Lebel M. Chronic nitric oxide inhibition aggravates hypertension in erythropoietin-treated renal failure rats. Clin Exp Hypertens. 2000;22:663-674.
25. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, Bode-Boger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol. 2005;16:892-898. Epub 2005 Feb 23.